

Chang-Li Wang

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7696018/publications.pdf>

Version: 2024-02-01

41
papers

902
citations

516710

16
h-index

501196

28
g-index

46
all docs

46
docs citations

46
times ranked

1312
citing authors

#	ARTICLE	IF	CITATIONS
1	Erlotinib Versus Gemcitabine Plus Cisplatin as Neoadjuvant Treatment of Stage IIIA-N2 EGFR-Mutant Non-Small-Cell Lung Cancer (EMERGING-CTONG 1103): A Randomized Phase II Study. <i>Journal of Clinical Oncology</i> , 2019, 37, 2235-2245.	1.6	193
2	Surgical Resection of SCLC: Prognostic Factors and the Tumor Microenvironment. <i>Journal of Thoracic Oncology</i> , 2019, 14, 914-923.	1.1	66
3	LncRNA H19 downregulation confers erlotinib resistance through upregulation of PKM2 and phosphorylation of AKT in EGFR-mutant lung cancers. <i>Cancer Letters</i> , 2020, 486, 58-70.	7.2	55
4	A single-arm, multicenter, safety-monitoring, phase IV study of icotinib in treating advanced non-small cell lung cancer (NSCLC). <i>Lung Cancer</i> , 2014, 86, 207-212.	2.0	47
5	Combined Small Cell Carcinoma of the Lung: Is It a Single Entity?. <i>Journal of Thoracic Oncology</i> , 2018, 13, 237-245.	1.1	47
6	Value of the Metastatic Lymph Node Ratio for Predicting the Prognosis of Non-Small-Cell Lung Cancer Patients. <i>World Journal of Surgery</i> , 2012, 36, 455-462.	1.6	44
7	Clinical Significance of 4L Lymph Node Dissection in Left Lung Cancer. <i>Journal of Clinical Oncology</i> , 2018, 36, 2935-2942.	1.6	36
8	The Function of SARI in Modulating Epithelial-Mesenchymal Transition and Lung Adenocarcinoma Metastasis. <i>PLoS ONE</i> , 2012, 7, e38046.	2.5	35
9	Society for Translational Medicine consensus on postoperative management of EGFR-mutant lung cancer (2019 edition). <i>Translational Lung Cancer Research</i> , 2019, 8, 1163-1173.	2.8	34
10	Osteopontin Combined With CD44v6, a Novel Prognostic Biomarker in Non-Small Cell Lung Cancer Undergoing Curative Resection. <i>Annals of Thoracic Surgery</i> , 2013, 96, 1943-1951.	1.3	33
11	Clinical evaluation of stereotactic radiation therapy for recurrent or second primary mediastinal lymph node metastases originating from non-small cell lung cancer. <i>Oncotarget</i> , 2015, 6, 15690-15703.	1.8	27
12	Osteopontin-Expressing Macrophages in Non-Small Cell Lung Cancer Predict Survival. <i>Annals of Thoracic Surgery</i> , 2015, 99, 1140-1148.	1.3	21
13	Claudin-3 expression increases the malignant potential of lung adenocarcinoma cells: role of epidermal growth factor receptor activation. <i>Oncotarget</i> , 2017, 8, 23033-23047.	1.8	21
14	Prognostic Value of the Lymph Node Ratio in Stage III Gastric Cancer Patients Undergoing Radical Resection. <i>PLoS ONE</i> , 2014, 9, e96455.	2.5	20
15	Tumor-associated macrophages (TAMs)-derived osteopontin (OPN) upregulates PD-L1 expression and predicts poor prognosis in non-small cell lung cancer (NSCLC). <i>Thoracic Cancer</i> , 2021, 12, 2698-2709.	1.9	20
16	Acquired small cell lung cancer resistance to Chk1 inhibitors involves Wee1 upregulation. <i>Molecular Oncology</i> , 2021, 15, 1130-1145.	4.6	18
17	Urinary malate dehydrogenase 2 is a new biomarker for early detection of non-small cell lung cancer. <i>Cancer Science</i> , 2021, 112, 2349-2360.	3.9	18
18	Claudin-1 correlates with poor prognosis in lung adenocarcinoma. <i>Thoracic Cancer</i> , 2016, 7, 556-563.	1.9	16

#	ARTICLE	IF	CITATIONS
19	miR-31-5p modulates cell progression in lung adenocarcinoma through TNS1/p53 axis. <i>Strahlentherapie Und Onkologie</i> , 2022, 198, 304-314.	2.0	14
20	Osteopontin knockdown suppresses non-small cell lung cancer cell invasion and metastasis. <i>Chinese Medical Journal</i> , 2013, 126, 1683-8.	2.3	14
21	Detection of circulating genetically abnormal cells in peripheral blood for early diagnosis of non-small cell lung cancer. <i>Thoracic Cancer</i> , 2020, 11, 3234-3242.	1.9	12
22	Alteration in gene expression profiles of thymoma: Genetic differences and potential novel targets. <i>Thoracic Cancer</i> , 2019, 10, 1129-1135.	1.9	11
23	Systematic identification of CDC34 that functions to stabilize EGFR and promote lung carcinogenesis. <i>EBioMedicine</i> , 2020, 53, 102689.	6.1	11
24	The preoperative platelet distribution width: A predictive factor of the prognosis in patients with non-small cell lung cancer. <i>Thoracic Cancer</i> , 2020, 11, 918-927.	1.9	11
25	Bevacizumab-Induced Mitochondrial Dysfunction, Endoplasmic Reticulum Stress, and ERK Inactivation Contribute to Cardiotoxicity. <i>Oxidative Medicine and Cellular Longevity</i> , 2021, 2021, 1-11.	4.0	11
26	A prognostic nomogram based on a new classification of combined micropapillary and solid components for stage IA invasive lung adenocarcinoma. <i>Journal of Surgical Oncology</i> , 2022, 125, 796-808.	1.7	9
27	Clinical recommendations for perioperative immunotherapy-induced adverse events in patients with non-small cell lung cancer. <i>Thoracic Cancer</i> , 2021, 12, 1469-1488.	1.9	7
28	A consensus on immunotherapy from the 2017 Chinese Lung Cancer Summit expert panel. <i>Translational Lung Cancer Research</i> , 2018, 7, 428-436.	2.8	7
29	TPP1 OB-fold domain protein suppresses cell proliferation and induces cell apoptosis by inhibiting telomerase recruitment to telomeres in human lung cancer cells. <i>Journal of Cancer Research and Clinical Oncology</i> , 2019, 145, 1509-1519.	2.5	6
30	Validation of the Chinese version of EORTC QLQ-BM22 in patients with bone metastases. <i>Supportive Care in Cancer</i> , 2016, 24, 1019-1024.	2.2	4
31	<sc>CITED4</sc> enhances the metastatic potential of lung adenocarcinoma. <i>Thoracic Cancer</i> , 2021, 12, 1291-1302.	1.9	4
32	Identification of a <sc>DNA</sc> damage repair <sc>gene-related</sc> signature for lung squamous cell carcinoma prognosis. <i>Thoracic Cancer</i> , 2022, , .	1.9	4
33	A consensus on liquid biopsy from the 2016 Chinese Lung Cancer Summit expert panel. <i>ESMO Open</i> , 2017, 2, e000174.	4.5	3
34	Tumor Differentiation and EGFR Mutation Associated with Disease-Free Survival in Stage IA Lung Adenocarcinoma Patients with Curative Surgery. <i>Cancer Management and Research</i> , 2020, Volume 12, 12549-12556.	1.9	3
35	Abstract CT041: ORIENT-3: A randomized, open-label, phase 3 study of sintilimab versus docetaxel in previously treated advanced/metastatic squamous non-small-cell lung cancer (sqNSCLC). <i>Cancer Research</i> , 2021, 81, CT041-CT041.	0.9	3
36	Survival study of neoadjuvant versus adjuvant chemotherapy with docetaxel combined carboplatin in resectable stage IB to IIIA non-small lung cancer.. <i>Journal of Clinical Oncology</i> , 2013, 31, 7537-7537.	1.6	3

#	ARTICLE	IF	CITATIONS
37	Safety and efficacy results of a phase IV, open-label, multicenter, safety-monitoring study of icotinib in treating advanced non-small cell lung cancer (NSCLC): ISAFE study.. Journal of Clinical Oncology, 2013, 31, e19161-e19161.	1.6	3
38	Sorting and gene mutation verification of circulating tumor cells of lung cancer with epidermal growth factor receptor peptide lipid magnetic spheres. Thoracic Cancer, 2020, 11, 2887-2895.	1.9	2
39	Final overall survival for CSLC 0501: Phase 3 study of adjuvant versus neoadjuvant chemotherapy with docetaxel combined carboplatin for resectable stageâ...B-â...A non-small cell lung cancer.. Journal of Clinical Oncology, 2018, 36, 8508-8508.	1.6	1
40	The role of chemokine receptor CXCR7 in lung cancer. Clinical Oncology and Cancer Research, 2010, 7, 342-346.	0.1	0
41	Prognostic factors and combined histologies in 205 resected small cell lung cancer (SCLC) patients.. Journal of Clinical Oncology, 2017, 35, e20009-e20009.	1.6	0